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Abstract
Background: Patients with chronic obstructive pulmonary disease (COPD) can experience 'exacerbations' of
their conditions. An exacerbation is an event defined in terms of subjective descriptors or symptoms, namely
dyspnoea, cough and sputum that worsen sufficiently to warrant a change in medical management. There is a need
for reliable markers that reflect the pathological mechanisms that underlie exacerbation severity and that can be
used as a surrogate to assess treatment effects in clinical studies. Little is known as to how existing study variables
and suggested markers change in both the stable and exacerbation phases of COPD. In an attempt to find the best
surrogates for exacerbations, we have reviewed the literature to identify which of these markers change in a
consistent manner with the severity of the exacerbation event.
Methods: We have searched standard databases between 1966 to July 2004 using major keywords and terms.
Studies that provided demographics, spirometry, potential markers, and clear eligibility criteria were included in
this study. Central tendencies and dispersions for all the variables and markers reported and collected by us were
first tabulated according to sample size and ATS/ERS 2004 Exacerbation Severity Levels I to III criteria. Due to
the possible similarity of patients in Levels II and III, the data was also redefined into categories of exacerbations,
namely out-patient (Level I) and in-patient (Levels II & III combined). For both approaches, we performed a fixed
effect meta-analysis on each of the reported variables.
Results: We included a total of 268 studies reported between 1979 to July 2004. These studies investigated
142,407 patients with COPD. Arterial carbon dioxide tension and breathing rate were statistically different
between all levels of exacerbation severity and between in out- and in-patient settings. Most other measures
showed weak relationships with either level or setting, or they had insufficient data to permit meta-analysis.
Conclusion: Arterial carbon dioxide and breathing rate varied in a consistent manner with exacerbation severity
and patient setting. Many other measures showed weak correlations that should be further explored in future
longitudinal studies or assessed using suggested mathematical modelling techniques.
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Background
Chronic obstructive pulmonary disease (COPD) is a respi-
ratory disease characterized by an airflow limitation and
inflammation of the lower airways [1]. As the disease
worsens, some patients experience 'exacerbations' of their
principal symptoms of dyspnoea, cough and sputum.
These exacerbations frequently result in a visit to a general
practitioner's office or to a local hospital for treatment.
Exacerbations occur in COPD patients at a median of
three times a year with half of them being unreported [2-
4]. The heterogeneity of COPD exacerbations make them
difficult to define, classify and manage due to their range
of symptoms, varied treatment requirements, seasonal
occurrence, and ambiguous aetiology [5-14].
To address this problem, attempts have been made to
develop a consensus definition for COPD exacerbations
[15]. Recently, the American Thoracic Society (ATS) and
European Respiratory Society (ERS) adopted the follow-
ing definition: 'an event in the natural course of the disease
that is characterised by a change in the patient's baseline dysp-
nea, cough and sputum beyond day-to-day variability sufficient
to warrant a change in management' [1].
The severity of an exacerbation has been also difficult to
classify despite the various schemes that have been pro-
posed to deal with this issue [4,15-17]. The ATS and ERS
have also jointly suggested a classification based upon
severity and the type of medical management used, i.e.,
Exacerbation Level I is home treatment, Level II is hospi-
talization, and Level III is specialised care [1]. The aim of
this scheme is to improve the existing management of
exacerbations and to serve as an aid in the assessment of
treatment efficacy.
Different operational definitions for COPD exacerbations
have been proposed in the past and these have helped
determine their relative importance, in particular their
relationship to COPD progression [1-17]. However, these
definitions have relied primarily on symptoms, and this
along with the absence of a standard classification for the
degree of symptom severity, has delayed the development
of new therapies for this condition. The current therapies
for exacerbations have been evaluated based on their abil-
ity to reduce symptoms, and to improve a patient's forced
expiratory volume in one second (FEV1) since the latter is
strongly correlated with COPD mortality. However, FEV1
does not discriminate well between the stable and exacer-
bative states of COPD, particularly during the later stages
of this disease. Hence, the development of biological
markers, or biomarkers that are more sensitive and spe-
cific to the severity of COPD exacerbations would provide
investigators with new insights and directions for further
research.
At this time, only a few clinical variables or inflammatory
mediators have been shown to be associated with COPD
exacerbations and their related morbidity and mortality.
Some of those include: age [18-20]; FEV1, forced vital
capacity and peak expired flow [19,21,22]; body mass
index [20]; albumin [20,22,23]; sodium [23]; pH [24,25];
eosinophils [26-29]; interleukins 6 and 8 [29-32]; fibrin-
ogen [31]; and C-reactive protein [33]. Significant clinical
events such as the number of exacerbations per year, the
number of hospital admissions per year, time to relapses,
and days in hospital have been regarded as useful meas-
ures in clinical studies designed to assess drug efficacy and
cost-effectiveness as well as to standardize existing hospi-
tal support programs for COPD [34-39]. However, it is
not known how these measures change with increasing
severity of COPD exacerbations.
Therefore, we have surveyed the medical literature to
identify which of the commonly accepted variables and
suggested markers for COPD exacerbations change
according to the ATS/ERS' levels of exacerbation severity.
The long-term aim of our work is to assess the sensitivity
and specificity of potential markers for use in future
COPD studies as well as to determine how such markers
can be further studied and fully integrated into the devel-
opment of new drugs for COPD.
Methods
Search strategy, study selection and overall objectives
We searched standard databases since 1966 using medical
search headings and related terms as obtained from major
consensus documents related to COPD exacerbations.
The major keywords were 'exacerbation', 'unstable',
'acute', 'bronchitis', and variants of the term 'COPD'. This
phase of our search retrieved a total of 843 citations. For
these citations, we read the title and abstract of each cita-
tion so as to exclude citations that concerned exacerba-
tions of coronary artery disease, myocardial infarction,
cystic fibrosis, asthma, pulmonary emboli, and commu-
nity pneumonia. Citations for case studies, letters,
reviews, meta-analyses, and animal studies were also
excluded.
After this initial screening, we identified 387 citations to
papers that were of possible interest. We retrieved the orig-
inal articles in electronic and hard copy forms, and then
critically read each article. As a result of this step, we
arrived at a total of 268 studies in our final review and
analyses. We selected these studies based on the availabil-
ity of demographics, spirometry, clear study eligibility cri-
teria, and the potential markers being used to assess
exacerbations.
The objectives of this literature review and data analyses
were to determine which of the baseline measures com-Respiratory Research 2006, 7:74 http://respiratory-research.com/content/7/1/74
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monly used in COPD exacerbation studies change with
the extent of the exacerbation and disease severity, and to
determine whether COPD exacerbations can be modelled
as 'events' or 'time-to-event' in future investigations.
Data abstraction methods
Initially, we considered various exacerbation definitions
and classification schemes, in particular, those suggested
by Rodriguez-Roisin [15] as well as those described by
Pauwels and colleagues [17]. However, we determined
that the ATS/ERS' operational classification of exacerba-
tion severity [1] was the most sensible and feasible system
for systematically assessing the patient baseline character-
istics and biomarker information from the majority of
published studies. We therefore used this classification
scheme and the related clinical history, physical findings
and diagnostic procedures for managing exacerbations to
perform our data abstraction. From each study, we
retrieved the reported demographics, spirometry, smok-
ing status, clinical, cytological and biochemical variables
as well as suggested markers of the severity of the exacer-
bation at baseline conditions, i.e., immediately prior to,
or during the exacerbation event but before the time in
which the intervention of interest was investigated (Table
1). Whenever such variables were measured in stable con-
ditions, we also abstracted this information. For each
study, we noted the type of definition used to define an
exacerbation such as symptom- or event-based as well as
the research question asked, the experimental design
used, any sponsorship, and the presence or absence of
data from individual study patients. Data was then further
organized according to sample size and smoking status
when available. Cytological and biochemical data were
also classified according to their collection methods.
These included sputum induction, bronchial biopsy,
bronchoalveolar lavage (BAL), exhaled breath sampling,
and blood sampling.
We were also aware of the possibility that for some study
groups in severity Levels II and III (as per the ATS/ERS cri-
teria) included in this review may have experienced a sim-
ilar quality of care or medical management that was not
reported adequately in the original publication. In
attempt to correct for this problem, we combined the
exacerbation data from Levels II and III into an 'in-patient'
category and then compared it to Level I that we regarded
as the 'out-patient' category.
Statistical methods
We collected and calculated study means, medians, stand-
ard errors, standard deviations, 95% confidence interval,
and inter-quartile ranges using the statistical algorithms in
Microsoft Excel 2002. We then conducted fixed effect
meta-analyses to obtain mean point estimates, 95% con-
fidence intervals, and two standard deviations for each
exacerbation level [40]. Exacerbation Severity Levels I and
II, II and III, and I and III were each compared using a two-
tailed Z-test. The alpha level of p < 0.05 was adjusted for
multiple testing according to the Bonferroni correction
procedure [41]. In the event that a specific exacerbation
severity level had a large number of studies in which only
median data were available, the data were considered to
be normally distributed and medians were treated as
means. Since many studies did not publish data for indi-
vidual patients, we were limited in addressing non-nor-
mality in the data by using a log10-transformation.
We again performed a fixed effect meta-analysis to obtain
mean point estimates, 95% confidence intervals, and two
standard deviations for in-patient and out-patient catego-
ries of each measure. We then compared each category
using a two-tailed Z-test and a p-value of 0.05.
Results
Description of studies and study subjects
Our search strategy yielded 268 suitable studies that met
our selection criteria. These studies were published
between 1979 and July 2004 – Week 2. (The references for
these studies can be found at the LACDR Division of Phar-
macology website [42]). The total number of study sub-
jects included in this review was 142,407. Of this group,
18% fell in Exacerbation Severity Level I, 78% in Level II,
and 4% in Level III. When we re-analysed the data accord-
ing to out- or in-patient settings, 18% were out-patients
and 82% in-patients.
Meta-analyses of typical study demographics showed that
there was significant overlap in 95% confidence intervals
and study data distributions for the three exacerbation
severity levels except for age where study patients in Level
II had a mean age of 64.2 years (95% confidence interval
(CI): 62.9 to 65.5 years) compared to 68.0 years (95% CI:
65.9 to 70.1 years) for patients in Level III (p = 0.002)
(Table 2). When the demographics were re-analyzed
according to patient settings, we determined that only
body mass index was statistically different between the
out-patient setting (mean point estimate: 26.2 kg/m2;
95% CI: 23.8 to 28.7 kg/m2) and the in-patient setting
(mean point estimate: 23.4 kg/m2; 95% CI: 22.5 to 24.3
kg/m2) (p = 0.038) (Table 3).
Relationship of different variables and biomarkers with 
exacerbation severity and patient setting
The spirometry measures Forced Expired Volume in 1 Sec-
ond (FEV1) and Forced Vital Capacity (FVC), both in per-
cent predicted, decreased from Exacerbation Levels I to II
(p < 0.017) but remained unchanged from Levels II to III
(Figure 1A and 1C, respectively). However, when Levels II
and III were combined to create an 'in-patient' category
for each of these variables, there was a statistically signifi-Respiratory Research 2006, 7:74 http://respiratory-research.com/content/7/1/74
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cant decrease for the in-patients versus the out-patients (p
< 0.05) (Figure 1B and 1D, respectively). We also
observed the same trend for FEV1/FVC (Figure 2A and 2B).
For all other spirometry measures, there were too few
studies available in Level III for meta-analysis.
We found for smoking that pack years increased with exac-
erbation severity, but only Levels I and II were statistically
different (p = 0.015) (Figure 2C). When we compared
pack years between patient settings, it was statistically
higher for the in-patients than the out-patients (p =
0.010) (Figure 2D).
In terms of the hemodynamic measures, only heart rate
showed a statistically significant difference being higher
in Level II than Level I (p = 0.014) with no difference
Table 1: Commonly Accepted Measures and Potential Markers Associated with COPD Exacerbations
Demographics Age; Gender; Height; Weight; Body Mass Index (BMI); Disease Years; Pack-Years.
Spirometry/Respiratory Status Measures Forced Expired Volume in One Second – FEV1 (litres and % predicted); Forced Vital Capacity – FVC 
(litres and % predicted); FEV1/FVC Ratio; Breathing Rate; Oxygenation Saturation (pulse and arterial); 
Peak Expired Flow Rate (PEFR); Fraction of Inspired Oxygen (FiO2); Intrinsic PEEP, Arterial Oxygen 
Tension (PaO2); Arterial Carbon Dioxide Tension (PaCO2); PaO2/FiO2 Ratio; Sputum Production.
Dyspnea Measures Baseline Dyspnea Index (BDI); Translational Dyspnea Index (TDI); Medical Research Council (MRC) 
Dyspnea Scale; Borg Dyspnea Score; American Thoracic Society (ATS) Dyspnea Score.
Functional Challenge & Quality of Life 
Measures
6 Minute Walking Distance (6MWD); β2-Agonist Reversibility; Adenosine Monophosphate, 
Methacholine or Histamine Challenge; St. George's Respiratory Questionnaire (SGRQ).
Haemodynamic Measures Systolic Blood Pressure; Diastolic Blood Pressure; Arterial Blood Pressure; Heart Rate; Cardiac 
Output.
Electrocardiogram Measures Lead II; Lead aVF; P Wave Axis-degrees.
Blood Electrolyte, pH and Protein 
Measures
Sodium; Potassium; Chloride; Bicarbonate; Glucose; pH; Phosphate; Urea; Albumin; Haemoglobin; 
Creatinine.
Exacerbation-Related Measures Number of Exacerbations Per Year (or in Past Year); Number of Exacerbations Per Patient-Year; 
Number of Exacerbations Requiring Oral Corticosteroids Per Patient-Year; Number of Exacerbation 
Related Infections in Past Year; Days in Hospital; Days Per Patient-Year in Hospital; Days in Intensive 
Care Unit; Days on Mechanical Ventilation; Number of Unscheduled or Scheduled GP Visits in Past 
Year; Time to First Exacerbation.
Hospital-Related Measures Number of Admissions in a Year; Number of Admissions Per Patient-Year; Number of Emergency 
Department Visits in Past Year; Time in the Emergency Department; Number of Patients Hospitalized 
in Past Year; Number of Patients Readmitted in Past Year; Number of Patients Relapsed in Past Year; 
Ventilation Type – Non-Invasive Positive Pressure Ventilation (NIPPV), Invasive Mechanical Ventilation 
(IMV) or Iron Lung; Admission to ICU; Mortality in Intensive Care Unit; Mortality in Hospital; 
Simplified Acute Physiology II Score (SAPS II); Acute Physiology And Chronic Health Evaluation II 
(APACHE II); Glasgow Coma Score (GCS).
Reported Comorbidities – Presence/
Absence; Number & Percent of Subjects
Charlson Comorbidity Index; Cardiovascular Disease; Cor Pulmonale; Congestive Heart Failure/
Insufficiency; Coronary Heart Disease; Ischaemic Heart Disease; Cardiac Arrhythmia; Hypertension; 
Pulmonary Oedema; Cerebrovascular Disease; Renal Disease; Liver Disease; Gastrointestinal Disease; 
Peripheral Vascular Disease; Endocrine Disease; Diabetes Mellitus; Cancer; Deep Vein Thrombosis; 
Pulmonary Emboli + Deep Vein Thrombosis; Bronchiectasis; Asthma; Depression; Emphysema; 
Comorbidity Present, Excluded from Study, or Not Described.
Reported Causes of Exacerbations – 
Presence/Absence; Number & Percent of 
Subjects
Pneumonia; Sepsis; Bronchospasm; Viral Infection; Bronchial Infection; Infection; Cardiac Insufficiency/
Heart Failure; Cardiac Arrhythmia; Pulmonary Emboli; Unknown Cause.
Reported Drug Information – Presence/
Absence; Number & Percent of Subjects
Beta Agonists – Inhaled, Short-Acting, Long-Acting, Oral/IV Systemic; Corticosteroids – Inhaled, Oral/
IV Systemic; Theophylline; Xanthines; Bronchodilators; Anticholinergics; Long-Term Oxygen Therapy 
(LTOT); Oxygen Supplementation; Beta-Agonist-Corticosteroid & Beta-Agonist-Anticholinergic 
Combinations; Antibiotics; Mucolytics; Expectorants; Antitussives; Diuretics; Oral Anticoagulants; 
Patient Compliance.
Bacterial Information – Number of 
Patients/Number of Isolates
S. pneumoniae; H. influenzae; M. catarrhalis; P. aeruginosa; B. catarrhalis; H. parainfluenza; S. aureus; C. 
pneumoniae; E. coli; OTHER: K. pneumoniae, Enterobacteriaceae, Pseudomonas Species, Alpha-Haemolytic 
Streptococci, Acinetobacter, M. pneumoniae, Legionella Species.
Viral Information – Number of Patients/
Number of Isolates
Influenza Virus A & B; Parainfluenza V1, V2 & V3; Adenovirus; Respiratory Syncytial Virus (RSV); 
Picornavirus; Rhinovirus; Coronavirus.
Cytological Measures – Local (Sputum, 
Bronchoalveolar Lavage (BAL), Biopsy); 
Systemic (Plasma or Serum)
Neutrophils; Macrophages; Eosinophils; Lymphocytes (White Blood Cells).
Biochemical Measures – Local (Exhaled, 
Sputum, BAL, Biopsy); Systemic (Plasma 
or Serum)
Leukotriene B4 (LTB4); 8-Isoprostane (8IPT); Elastase; Myeloperoxidase (MPO); Secretory 
Leukoprotease Inhibitor (SLPI); Endothelin-1 (ET-1); Interleukin-8 (IL8); Interleukin-6 (IL6); 
Interleukin-10 (IL10); Nitric Oxide; Tumour Necrosis Factor (TNFα); C-Reactive Protein (CRP); 
Fibrinogen.
Many study variables were measured at or around the time of the exacerbation. If these variables were measured in the stable condition of these 
COPD patients, i.e., measurements were taken weeks or months prior to the exacerbation, then these were also obtained.Respiratory Research 2006, 7:74 http://respiratory-research.com/content/7/1/74
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between Levels II and III (Figure 3A). Heart rates were also
higher for in-patients than out-patients (p = 0.011) (Fig-
ure 3B).
The clinical measures of dyspnoea, i.e., the breathing rate
(Figure 3C) and Borg dyspnoea score, tended to increase
from Levels I to II and then decrease from Levels II to III.
However, only breathing rate demonstrated clear statisti-
cal differences between the three levels (p < 0.017). Only
Levels II and III of the Borg Dyspnoea Score were statisti-
cally different (p < 0.001); a statistical comparison of
these levels with Level I was not possible due to lack of
data. When patient settings were compared, only breath-
ing rate showed a clear statistical difference being statisti-
cally lower for in-patients than out-patients (p = 0.003)
(Figure 3D).
Exacerbation Levels II and III were statistically different
with respect to pH (p = 0.003) and bicarbonate (p =
0.002) in that pH decreased from Level II to III whereas
bicarbonate increased. However, there was insufficient
Level I data for each variable to allow for statistical com-
parisons with the other Levels. There was also insufficient
data available to compare out-patients with in-patients.
In terms of blood gas measures studied, only arterial car-
bon dioxide tension (PaCO2) showed a statistically signif-
icant increase with increasing exacerbation severity (p <
0.017) (Figure 4A) as well as out- versus in-patients (p <
0.05) (Figure 4B). In the case of oxygen saturation, it grad-
ually decreased with increasing exacerbation severity with
statistically significant differences between Levels I and II
(p < 0.001) as well as Levels I and III (p = 0.011) (Figure
4C). It also decreased going from an out-patient to an in-
patient setting (P < 0.001) (Figure 4D).
The six minute walking distance challenge test seemed to
show a decreasing trend with increasing exacerbation
severity but such changes did not reach statistical signifi-
cance. This was also the case when the out- and in-patients
Table 2: Typical Subject Demographics According to ATS/ERS 2004 Exacerbation Severity Level
Variable/Exacerbation 
Severity Level†
Total Studies* Total Subjects# Point Estimate 
(95% CI)
Study Data 
Distributions 
(± 2SD)
Significance Test‡
Z Test P Value
Age (years) 182 27,930 Levels
Level I 71 16,917 66.0 (64.6 – 67.4) 51.2 – 80.8 I vs. II 0.067 (NS)
Level II 70 7,300 64.2 (62.9 – 65.5) 52.1 – 76.3 II vs. III 0.002
Level III 43 3,713 68.0 (65.9 – 70.1) 53.0 – 83.0 I vs. III 0.12 (NS)
Height (cm) 27 3,154 Levels
Level I 14 2,581 169.7 (166.4 – 173.0) 155.1 – 184.3 I vs. II 0.25 (NS)
Level II 9 247 167.1 (164.0 – 170.2) 157.5 – 176.6 II vs. III 0.54 (NS)
Level III 4 326 169.1 (163.4 – 174.7) 157.3 – 180.9 I vs. III 0.85 (NS)
Weight (kg) 37 4,168 Levels
Level I 15 3,176 72.8 (67.5 – 78.1) 46.9 – 98.7 I vs. II 0.36 (NS)
Level II 12 290 69.3 (63.8 – 74.7) 49.4 – 89.1 II vs. III 0.26 (NS)
Level III 10 702 63.6 (55.3 – 71.9) 35.5 – 91.7 I vs. III 0.067 (NS)
Body-Mass Index (kg/m2) 29 4,250 Levels
Level I 6 2,273 26.2 (23.8 – 28.7) 18.5 – 34.0 I vs. II 0.037 (NS)
Level II 19 1,729 23.4 (22.4 – 24.4) 19.5 – 27.3 II vs. III 0.84 (NS)
Level III 7 248 23.6 (21.2 – 26.0) 17.1 – 30.1 I vs. III 0.14 (NS)
Disease Years 21 8,606 Levels
Level I 15 8,354 10.9 (7.8 – 14.1) 0 – 26.4 I vs. II 0.65 (NS)
Level II 5 228 12.9 (5.0 – 20.8) 0 – 30.2 II vs. III 0.67 (NS)
Level III 2 24 16.2 (3.9 – 28.4) 0 – 33.5 I vs. III 0.42 (NS)
Symbols and Abbreviations: *Bold numbers indicate total studies (without duplicates) for the specific variable of interest; # Bold numbers 
indicate total subjects for all COPD exacerbation severity levels with respect to the specific variable of interest; † Exacerbation severity levels are 
based on the following ATS/ERS 2004 operational classification scheme: Level I – treated at home; Level II – requires hospitalisation ; and Level III – 
leads to respiratory failure; ‡ Exacerbation Levels II and III were each compared to Level I using a two-tailed Z-test in which the alpha level was 
adjusted according to the Bonferroni Correction procedure to account for multiple testing; and NS = Non-significant difference.Respiratory Research 2006, 7:74 http://respiratory-research.com/content/7/1/74
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were compared. Many other variables related to spirome-
try, respiratory status, exacerbation and hospital event cat-
egories also did not change significantly with
exacerbation severity or out- and in-patients (See addi-
tional file 1). There was not enough data in the bacteriol-
ogy and virology categories to permit any meta-analyses.
Of the 268 studies sampled, only half contained data
about the biochemical variables.
Discussion
We conducted this review of the COPD exacerbation liter-
ature to determine which commonly-accepted baseline
variables and suggested markers changed in a consistent
manner with the severity of COPD exacerbations. As our
index of COPD severity, we used the recently published
ATS/ERS operational classification of exacerbation sever-
ity for medical management. This is because most of the
published literature rarely provides sufficient details to
characterise the severity of a patient's exacerbation. In
addition, we also analyzed the same data according to
out- and in-patient settings so as to account for possible
overlaps in medical management between Levels II and III
but were not reported in the original publication.
The long-term aim of our work is to improve the quality
and applicability of exacerbation management through
the identification of sensitive and specific markers that
can be used for the assessment of treatment effects. This
review identified a few potential markers of exacerbation
severity.
When we assessed the spirometry measures FEV1 and FVC
in % predicted, as well as FEV1/FVC, we observed statisti-
cally significant differences with exacerbation severity,
and between out- and in-patients (Figures 1A–D and 2A–
B). One draw-back was the paucity of such information in
Level III studies. This confirms the clinical situation that
as exacerbations worsen and more specialised care is
required, spirometry measurements are less likely under
baseline conditions or during an exacerbation [14]. Thus,
such data is rare in many published studies.
The number of smoking-related pack years increased with
exacerbation severity and showed a clear difference
between out- and in-patient settings (Figures 2C and 2D),
a finding that is consistent with the idea that the more a
COPD patient smokes, and for longer, the higher the like-
lihood that COPD exacerbations will be more severe.
According to the mean point estimates obtained in this
Table 3: Typical Subject Demographics According to Out-Patient and In-patient Settings
Variable/Patient 
Setting Type†
Total Studies* Total Subjects# Point Estimate 
(95% CI)
Study Data 
Distributions 
(± 2SD)
Significance Test‡
Z Value P Value
Age (years) 182 27,930 0.78 0.44 (NS)
Out-patient 71 16,917 66.0 (64.6 – 67.4) 51.2 – 80.8
In-patient 112 11,013 65.3 (64.2 – 66.4) 52.3 – 78.3
Height (cm) 27 3,154 1.00 0.32 (NS)
Out-patient 14 2,581 169.7 (166.4 – 173.0) 155.1 – 184.3
In-patient 13 573 167.5 (164.8 – 170.2) 157.5 – 177.6
Weight (kg) 37 4,168 1.48 0.14 (NS)
Out-patient 15 3,176 72.8 (67.5 – 78.1) 46.9 – 98.7
In-patient 22 992 67.5 (62.9 – 72.1) 45.1 – 89.9
Body-Mass Index 
(kg/m2)
29 4,250 2.08 0.038
Out-patient 6 2,273 26.2 (23.8 – 28.7) 18.5 – 34.0
In-patient 24 1,977 23.4 (22.5 – 24.3) 19.1 – 27.7
Disease Years 21 8,606 0.78 0.44 (NS)
Out-patient 15 8,354 10.9 (7.8 – 14.1) 0 – 26.4
In-patient 6 252 13.9 (7.1 – 20.7) 0 – 31.7
Symbols and Abbreviations: *Bold numbers indicate total studies (without duplicates) for the specific variable of interest; # Bold numbers 
indicate total subjects for out-patient and in-patient categories with respect to the specific variable of interest; † Out-patient category represents 
ATS/ERS 2004 Exacerbation Severity Level I (treated at home) and the in-patient category Levels II (requires hospitalisation) and III (leads to 
respiratory failure) combined; ‡ Outpatient and in-patient categories were compared using a two-tailed Z-test; and NS = Non-significant difference.Respiratory Research 2006, 7:74 http://respiratory-research.com/content/7/1/74
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Fixed Effect Meta-Analysis Results of Selected Spirometry Variables Figure 1
Fixed Effect Meta-Analysis Results of Selected Spirometry Variables. Graphs displayed are: A) FEV1 % Predicted 
(COPD Exacerbation Severity Levels I to III); B) FEV1 % Predicted (Out- versus In-patient Setting); C) FVC % Predicted (Levels 
I to III); and D) FVC % Predicted (Out- versus In-patient Setting). For each spirometry variable, the point estimates (point), 95% 
confidence intervals (box), and two standard deviations (bars) are presented for Levels I to III and out- & in-patient settings. 'N' 
signifies the total studies and 'n' is the total subjects. P < 0.017 is indicated for statistical comparisons of Level I versus II (*), II 
versus III (†), and I versus III (#) as well as P < 0.05 for comparison of out- versus in-patient setting (*).
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Fixed Effect Meta-Analysis Results of Selected Clinical Variables Figure 2
Fixed Effect Meta-Analysis Results of Selected Clinical Variables. Graphs displayed are: A) FEV1/FVC Ratio (Exacerba-
tion Severity Levels I to III); B) FEV1/FVC Ratio (Out- versus In-patient Setting); C) Pack Years (Levels I to III); and D) Pack 
Years (Out- versus In-patient Setting). For each clinical variable, the point estimates (point), 95% confidence intervals (box), 
and two standard deviations (bars) are presented for Levels I to III and out- & in-patient settings. 'N' signifies the total studies 
and 'n' is the total subjects. P < 0.017 is indicated for statistical comparisons of Level I versus II (*), II versus III (†), and I versus 
III (#) as well as P < 0.05 for comparison of out- versus in-patient setting (*).
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Fixed Effect Meta-Analysis Results of Selected Clinical Variables Figure 3
Fixed Effect Meta-Analysis Results of Selected Clinical Variables. Graphs displayed are: A) Heart Rate (Exacerbation 
Severity Levels I to III); B) Heart Rate (Out- versus In-patient Setting); C) Breathing Rate (Levels I to III); and D) Breathing Rate 
(Out- versus In-patient Setting). For each clinical variable, the point estimates (point), 95% confidence intervals (box), and two 
standard deviations (bars) are presented for Levels I to III and out- & in-patient settings. 'N' signifies the total studies and 'n' is 
the total subjects. P < 0.017 is indicated for statistical comparisons of Level I versus II (*), II versus III (†), and I versus III (#) as 
well as P < 0.05 for comparison of out- versus in-patient setting (*).
†
#
*
*
10 20 30 40
 Level I
(N=7;n=1213)
 Level II
(N=8;n=620)
 Level III
(N=27;n=1779)
Breaths / Minute
C
60 80 100 120 140
 Out-patient
(N=10;n=591)
 In-patient
(N=25;n=1813)
Heart Rate (bpm)
*
B
60 80 100 120 140
 Level I
(N=10;n=591)
 Level II
(N=7;n=329)
 Level III
(N=18;n=1484)
Heart Rate (bpm)
*
A
10 20 30 40
 Out-patient
(N=7;n=1213)
 In-patient
(N=35;n=2399)
Breaths / Minute
DRespiratory Research 2006, 7:74 http://respiratory-research.com/content/7/1/74
Page 10 of 14
(page number not for citation purposes)
Fixed Effect Meta-Analysis Results of Selected Clinical Variables Figure 4
Fixed Effect Meta-Analysis Results of Selected Clinical Variables. Graphs displayed are: A) Arterial Carbon Dioxide 
Tension, PaCO2(Exacerbation Severity Levels I to III); B) PaCO2 (Out- versus In-patient Setting); C) Percent Oxygen Saturation 
– Arterial & Pulse Measurements Combined (Levels I to III); and D) Percent Oxygen Saturation – Arterial & Pulse Measure-
ments Combined (Out- versus In-patient Setting). For each clinical variable, the point estimates (point), 95% confidence inter-
vals (box), and two standard deviations (bars) are presented for Levels I to III and out- & in-patient settings. 'N' signifies the 
total studies and 'n' is the total subjects. P < 0.017 is indicated for statistical comparisons of Level I versus II (*), II versus III (†), 
and I versus III (#) as well as P < 0.05 for comparison of out- versus in-patient setting (*).
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study, COPD patients with 40 to 60 pack-years of smok-
ing will experience an increase in the severity of COPD
exacerbations. However, our conclusion regarding this
finding is limited by there being data from only two stud-
ies at Level III.
Although heart rate varied little between Exacerbation
Levels II to III, it is important to note that it was substan-
tially elevated in patients (Figure 3A) with the clearest dif-
ference being between in- and out-patients. This is
possibly associated with the anxiety and dyspnea that
experienced when an exacerbation occurs. The increase in
heart rate of course increases the oxygen requirements of
the heart. The increased heart rate may also be the result
of underlying cardiovascular disease that is more promi-
nent in severe COPD patients [43].
The relationship of pH and bicarbonate to exacerbation
severity are consistent with the signs of respiratory acido-
sis evident in COPD patients with exacerbations
[1,24,25]. However, due to the shortage of data in Level I,
proper statistical conclusions about each of these varia-
bles are difficult to make. In relation to this, breathing rate
significantly increased from Levels I to II and then
decreased from Levels II to III (Figure 3C). The first obser-
vation may reflect components of the exacerbation epi-
sode (i.e., anxiety and dyspnea) as well as the
physiological need to breathe more to maintain adequate
blood gas levels. The reduction at Level III possibly reflects
the results of the specialized care where patients are given
ventilatory support so as to return the breathing rate to
normal. The Borg Dyspnea Score showed the same trend
as breathing rate, although insufficient data in Level I did
not allow for further comparisons. When out- and in-
patient data were compared for each of these variables,
only breathing rate demonstrated a clear statistical differ-
ence (Figure 3D). The Borg Dyspnoea Score on the other
hand did not have enough studies in the out-patient cate-
gory to perform any statistical test. Overall, the observed
trends were consistent with the fact that management of
dyspnoea is one of the main factors generating the high
hospital costs associated with COPD exacerbations [44].
In keeping with the direct measures of dyspnoea, arterial
carbon dioxide tension showed a clear relationship with
exacerbation severity and patient management settings
(Figures 4A and 4B) that is consistent with the conclu-
sions reported in the medical literature [20,45-47]. Arte-
rial oxygen tension in contrast did not change with
exacerbation severity or patient setting. Possibly this lack
of correlation reflects the immediate administration of
supplemental oxygen given to hypoxaemic patients in a
hospital setting. There was however a decreasing trend in
oxygen saturation with increasing exacerbation severity
and clear differences between out- and in-patient settings
(Figures 4C and 4D) that are consistent with the present
thinking on blood gas changes.
Most of the other commonly accepted measures and sug-
gested biomarkers poorly reflected exacerbation severity,
or the fact that there was not sufficient data to undertake
a meta-analysis (See additional file 1). This finding recalls
a 2001 US Department of Health and Human Services
report on exacerbation treatment outcomes from over 200
randomised controlled trials [14]. The aim of that study
was to create new guidelines to improve the management
of COPD exacerbations. That study also concluded that
the current literature was limited in terms of the number
of studies and the amount of detail available as well as the
reliability and accuracy of the clinical assessments used to
discriminate between COPD exacerbations and other
causes of worsening respiratory status. Thus, our observa-
tions agree with previous observations regarding the
assessment of the unstable COPD literature.
As previously discussed, most of the studies used for this
review were predominately with hospitalized patients
(Level II). However, most COPD occurs in an out-patient
setting (Level I) [48-53]. This has implications for our
study since the latter population was poorly represented.
Our basic categorisation was according to the ATS/ERS'
operational scheme for classifying the severity of COPD
exacerbations as well as to out- and in-patient categories.
To our knowledge, we are the first to undertake this type
of literature review and thus we were faced with a lack of
consistency in the definition of exacerbations as used in
the various studies. We tried to overcome this difficulty by
selecting and ranking clinical studies so as to improve the
comparability of subjects between studies.
We were also aware that the clinical studies we analysed
differed with respect to which comorbidities or identifia-
ble causes for exacerbations were reported. Most patients
were elderly and therefore were more likely to be suffering
from one or more co-existing diseases such as asthma or
cardiovascular disease. Such co-morbidity makes interpre-
tation of our findings more difficult with respect to the
true causes of exacerbations. If their aetiology could be
determined, then susceptible patients such as those in
Level I could be identified and new treatments developed
to help prevent their onset and related hospital costs.
Finally, the compatibility between the studies of COPD
exacerbation that we analysed may have been limited by
substantial variations in the time and location of studies.
Exacerbations are more likely in summer [5] but many
studies failed to report the time of year or the time period
for study implementation. Thus, seasonal effects, com-
bined with the low incidence of exacerbations per patient,Respiratory Research 2006, 7:74 http://respiratory-research.com/content/7/1/74
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could represent an inherent bias. In addition, different
institutions probably had different standards with respect
to diagnosis and management of COPD exacerbations
when these studies were performed. Such variations may
also explain any observed inconsistencies in our findings.
However, we attempted to overcome this possible bias in
Exacerbation Levels II and III by the subsequent re-analy-
sis of this data on the basis of out-patient and in-patient
settings.
As observed in The additional online file, there was a scar-
city of information particularly for biomarkers at different
exacerbation levels. It is also unclear to us whether any of
the variables that changed with exacerbation severity are
causally-related. Hence, longitudinal studies and/or less
restrictive eligibility criteria would be needed to address
all these questions. One difficulty in tackling such prob-
lems is the enormous amount of time and expense
involved in implementing such studies. In addition, the
current methods for data analysis in clinical studies have
limitations imposed by the assessment of the reduction in
frequency or total suppression of exacerbation episodes
(i.e. rare event or "non-event").
To overcome these drawbacks and obtain more accurate
evaluation of treatment effect on COPD exacerbations,
alternative analytical methods based, for example, on pre-
dictive mathematical models such as hidden Markov
chains or Bayesian forecasting should be tried. Such mod-
els can characterise and predict rare events without under-
taking a full-scale, long-term longitudinal study. This
approach to predicting rare events has been used previ-
ously in studies of migraine, epilepsy and various cardio-
vascular diseases where the size of treatment effect is
measured in terms of a reduction in the frequency of the
repetition of an event within a given probability or within
a given time period [54,55]. One example of a mathemat-
ical model development includes the use of a Markov
model to predict COPD exacerbation rates in a clinical
trial of the inhaled anticholinergic bronchodilator tiotro-
pium [56]. In this example, the model was developed on
the basis of prior knowledge of the exacerbation rate as
estimated from meta-analyses of randomised controlled
trial data. This gave the probabilities for COPD exacerba-
tions for different stages of COPD. In another study, a pro-
portional hazards model was used to identify risk factors
for COPD patients hospitalised due to an exacerbation
[44]. The current ATS/ERS guidelines for exacerbations do
not consider the implications of using probabilistic mod-
els as a means of assessing the severity of COPD exacerba-
tions or the effect of treatment [1]. A modelling approach
may offer new insights into which variables related to
COPD exacerbations should be investigated.
From a research planning perspective, our study findings
have generated some hypotheses and related considera-
tions that could be evaluated in future clinical trials. One
hypothesis is that the combination of variables that we
observed to change in our study (i.e., FEV1, FVC, FEV1/
FVC, arterial carbon dioxide, breathing rate, heart rate,
pack years, and oxygen saturation) could represent a new
definition for a 'severe' exacerbation event. Most defini-
tions in the literature, including the recent ATS/ERS defi-
nition, do not indicate any assessment of
(patho)physiological variables as signs of an exacerba-
tion. They simply regard the exacerbation as a worsening
of the normal day-to-day symptoms and/or an adjust-
ment in medical management [17]. A definition that
encompasses a clear set of objective measures would be
useful to medical practitioners who predominantly rely
on clinical judgement or past experiences for diagnosing
an exacerbation and its severity as well as for assessing
treatment effect.
Another important consideration for future clinical trials
is the assessment of treatment effect based on predictions
of exacerbation frequency and intensity. In other words,
the collection of data such as the rate of onset and resolu-
tion of an exacerbation from longitudinal studies could
be used to determine probabilities of second, third,
fourth, etc., exacerbation events in individual patients
[54]. The alteration of such probabilities with an experi-
mental treatment could be a more sensitive and reliable
approach for assessing treatment effect in clinical trials
than recording daily changes in symptoms or medical
management.
Lastly, our findings were obtained from COPD patients
that had experienced at least one exacerbation during the
study assessment period. In the same studies, there were
also patients who did not experience an exacerbation. This
indicates that a fraction of COPD patients may be
regarded as being susceptible to an exacerbation whereas
another fraction is 'exacerbation-free'. It would be inter-
esting to determine how the variables we identified in our
study change in the latter patient group according to FEV1.
Some published studies have stratified COPD patients on
the basis of exacerbation frequency; this is generally done
by categorising patients as having either 'infrequent' or
'frequent' exacerbations if they had less than or greater
than a mean of three exacerbations per year, respectively
[57]. In our study, we were unable to make this distinction
between COPD patients since many of the published
studies did not provide individual patient data on exacer-
bation frequency. We are currently investigating a com-
mercial database of clinical trials that will enable us to
look at patients with 'infrequent' or 'frequent' exacerba-
tions. The results of this work could help us better selectRespiratory Research 2006, 7:74 http://respiratory-research.com/content/7/1/74
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patients as well as identify potential markers for future
longitudinal studies.
Conclusion
The current management and treatment of COPD exacer-
bations is primarily dependent on the evaluation of the
symptoms rather than the signs related to the exacerba-
tion event. We found that arterial carbon dioxide tension
and breathing rate consistently varied with the severity of
COPD exacerbations and with in- versus out-patients.
Other commonly-accepted measures and suggested
biomarkers for exacerbations failed to show consistent
trends or lacked sufficient data to permit any meta-analy-
sis. We recommend the design of longitudinal studies
looking at the frequency of exacerbations as well as the
use of more advanced modelling techniques to improve
the selection of potential markers for the categorization of
the severity of COPD exacerbations and the assessment of
treatment effect in future studies.
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